Keya Medical
AI for Smarter Healthcare
contact
Keya Medical’s FFR CT analysis DEEPVESSEL® is now available in the USA.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
Diagnostic Solutions
Treatment Solutions
Solution Suites
Cardiology
Neurology
Pulmonology
Pathology
General Surgery
Cardio Suite
Stroke Suite
Diagnostic Solutions
Cardiology
Neurology
Pulmonology
Pathology
Treatment Solutions
Vascular Surgery
General Surgery
Solutions Suites
Cardio Suite
Stroke Suite
DeepVessel® FFR
Enabling better diagnosis and treatment of patients with coronary artery disease.
DEEPVESSEL FFR uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computer tomography angiograms. The software can reduce unnecessary invasive testing, improve patient safety, and lower the cost of cardiovascular testing.
DEEPVESSEL FFR is FDA Cleared, CE Marked, and NMPA Approved.
Comprehensive R&D Pipeline Solution Suites
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment followup.
Keya Medical: world’s leading AI medical device company
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. To learn more about Keya Medical, follow us on LinkedIn, Twitter, and Facebook.
Latest News
Subscribe to our monthly newsletter to receive exclusive news updates and medical AI insights.
Keya Medical’s FFR CT analysis DEEPVESSEL® is now available in the USA.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Let’s transform the future of healthcare together
Products
DeepVessel FFR
CuraRad-ICH
Solutions
All Solutions
Diagnostic Solutions
Treatment Solutions
Solution Suites
